Patent Grant
10626397
The present invention relates to a composition for inhibiting breast cancer stem cells containing a protein kinase D1 inhibitor and an anticancer adjuvant for preventing recurrence of breast cancer.
Breast cancer is the most common tumor and ranks top in causes of woman tumor-related deaths worldwide [1]. Despite efforts to improve the survival rate of patients, there are still problems related with breast cancer treatment including metastasis and drug resistance [2, 3]. Tumors consist of cancer stem cells (CSCs) and non-tumorigenic cells that form tumor mass [4]. The CSCs are considered as a cause of tumor, tumor metastasis, drug resistance, and tumor recurrence [5]. In particular, breast cancer stem cells (BCSCs) has a characteristic of stem cells and are characterized by expression of cell surface markers CD44+/CD24− [6]. Different miRNAs are involved in the formation and regulation of human breast cancer stem cells [7], and according to preceding studies, ectopic expression of miR-34c inhibits migration of epithelial-mesenchymal cells and reduces self-renewal capacity in human breast cancer stem cells [8].
Serine/threonine-protein kinase D1 (PKD1) acts as diacylglycerol and protein kinase C (PKC) effectors to mediate stimulatory activity [9]. PKD/PKCμ related cellular processes were activated by two phosphorylations through PKC-dependent phosphorylation (Ser744/Ser748) and PKC-independent autophosphorylation (Ser910) [10-13]. Therefore, PRKD1 is considered as a major regulator in many cellular processes including a NF-kB signaling pathway, cell cycle progression, DNA synthesis, and regulation of other pathogenic conditions [14-16].
In breast cancer, microRNAs regulate apoptosis, tumor formation and angiogenesis. A major regulator of tumor suppression, miR-34, is a direct transcriptional target for a tumor inhibitor p53, and a miR-34a promoter region includes a p53-binding site [17]. In breast cancer studies, the miR-34a plays a role in inhibiting cell survival by up-regulating p53 after irradiation after DNA damage [18]. In addition, the miR-34a promoted tumor apoptosis by targeting Bcl-2 and SIRT1 [19]. Therefore, the miR-34a is associated with a target that induces breast cancer.
An object of the present invention is to provide pharmaceutical compositions for inhibiting breast cancer proliferation and metastasis more effectively.
Another object of the present invention is to provide an adjuvant for restoring drug sensitivity of anticancer agent-resistant breast cancer more effectively.
Yet another object of the present invention is to provide pharmaceutical compositions for inhibiting recurrence of breast cancer more effectively.
The present inventors found that PRKD1 overexpressed in MCF-7-ADR cells was inhibited by miR-34a. In addition, the PRKD1 activated self-renewal capacity in breast cancer stem cells through glycogen synthase kinase 3 (GSK3)/β-catenin signaling and contributed to the removal of drug resistance. These results indicate that the PRKD1 as a new target of miR-34a can play an important role in the treatment of human breast cancer.
The present invention relates to a pharmaceutical composition for inhibiting the growth of cancer stem cells containing a protein kinase D1 expression or activity inhibitor as an active ingredient.
Further, the protein kinase D1 of the present invention may have an amino acid sequence of SEQ ID NO: 1, and the protein kinase D1 is not limited to the amino acid sequence of SEQ ID NO: 1 and includes an analogue thereof.
Further, the protein kinase D1 expression inhibitor of the present invention may be any one selected from the group consisting of an antisense nucleotide complementarily binding to mRNA of a protein kinase D1 gene, a short interfering RNA, a short hairpin RNA, and miR34a.
Further, the protein kinase D1 activity inhibitor of the present invention may be any one selected from the group consisting of compounds that specifically bind to the protein kinase D1, peptides, peptide mimetics, aptamers, antibodies and CRT0066101.
Further, the cancer of the present invention may be selected by cancer stem cell markers CD44+ and CD24−.
Further, the cancer of the present invention is preferably one selected from the group consisting of breast cancer, liver cancer, intestine cancer, cervical cancer, kidney cancer, stomach cancer, prostate cancer, brain tumor, lung cancer, uterine cancer, colon cancer, bladder cancer, blood cancer and pancreatic cancer and more preferably breast cancer, but it is not limited thereto.
Further, in order to avoid recurrence and metastasis of cancer cells and completely remove cancer, beyond the limitations of current cancer therapies that only attack cancer cells, it is necessary to remove cancer stem cells by targeting the cancer stem cells having stem cell characteristics. The present invention may inhibit the growth of cancer stem cells, particularly breast cancer stem cells and inhibit the cancer stem cells to prevent cancer recurrence.
The present invention relates to a pharmaceutical composition for inhibiting proliferation and metastasis of breast cancer containing a protein kinase D1 expression or activity inhibitor as an active ingredient.
Further, the protein kinase D1 inhibitor may inhibit stemness of breast cancer cells.
The present invention relates to an anti-cancer adjuvant for preventing recurrence of breast cancer containing a protein kinase D1 expression or activity inhibitor as an active ingredient.
Further, since the composition of the present invention significantly inhibits the growth of breast cancer stem cells, the present invention relates to an anti-cancer adjuvant capable of inhibiting recurrence of breast cancer.
The present invention provides a method for inhibiting breast cancer stem cells including a step of treating a protein kinase D1 expression or activity inhibitor to a subject.
Further, the present invention provides a method for measuring prognosis of breast cancer including a step of determining recurrence of breast cancer by verifying whether the protein kinase D1 is expressed or activated in a subject.
The protein kinase D1 is expressed in the breast cancer stem cells, and when the protein kinase D1 is inhibited, the growth of the breast cancer stem cells is significantly inhibited, and thus, the protein kinase D1 expression or activity inhibitor may be usefully used for inhibition of the breast cancer stem cells. Further, since there is a risk of recurrence of breast cancer due to the breast cancer stem cells, prognosis of breast cancer may be measured by measuring whether the protein kinase D1 is expressed or activated.
The composition of the present invention may be used alone or in combination with radiation therapy, chemotherapy, and a method using a biological response modifier.
The composition of the present invention contains 0.0001 to 50 wt % with respect to the total weight of the therapeutic composition.
The composition of the present invention may further contain one or more active ingredients that exhibit the same or similar functions. The composition of the present invention may be administered orally or parenterally during clinical administration and used in the form of a general pharmaceutical preparation.
The composition of the present invention may be administered in a form of a composition that further includes a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier includes, for example, one or more of water, saline, phosphate buffered saline, dextrin, glycerol, ethanol, and combinations thereof. The composition may be formulated to provide a rapid release, or a sustained or delayed release of the active ingredient after administration.
When the inhibitor for the protein of the present invention is an antibody, the pharmaceutically acceptable carrier may consist of a minimum amount of auxiliary material such as a wetting agent, an emulsifying agent, a preservative or a buffer, which increase the storage life or effectiveness of a binding protein.
The composition of the present invention may include a pharmaceutically acceptable and physiologically acceptable adjuvant, and the adjuvant may include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, glydents or solubilizers.
In addition, the composition of the present invention may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the above-described active ingredients for administration.
The pharmaceutical carrier which is accepted in the composition formulated into a liquid solution is suitable for sterilization and living bodies and may use a saline solution, sterile water, a ringer's solution, buffered saline, an albumin injection solution, a dextrose solution, a maltodextrin solution, glycerol, ethanol and combinations of one or more components thereof, and if necessary, other general additives such as antioxidants, buffers, and bacteriostats may be added. Further, the pharmaceutical carrier may be formulated by injectable formulations such as aqueous solutions, suspensions, and emulsions, pills, capsules, granules or tablets by additionally adding diluents, dispersants, surfactants, binders and lubricants. Furthermore, the pharmaceutical carrier may be preferably formulated according to each disease or ingredient by using, as a proper method of the corresponding field, a method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton Pa.
The pharmaceutical formulations of the composition of the present invention may include granules, powders, coated tablets, tablets, capsules, suppositories, syrups, juices, suspensions, emulsions, drops or injectable solutions, and sustained release formulations of active compounds.
The composition of the present invention may be administered by a general method through intravenous, intraarterial, intraperitoneal, intramuscular, intraarterial, intraperitoneal, intrasternal, transdermal, intranasal, inhalation, topical, rectal, intraocular, or intradermal routes.
An “effective dose” means an amount required to achieve an effect of inhibiting the proliferation and metastasis of breast cancer and the growth of stem cells. Accordingly, the “effective dose” of the active ingredient of the present invention may be adjusted according to various factors including a type of disease, severity of the disease, types and contents of an active ingredient and other ingredients contained in the composition, a type of formulation, and an age, a weight, a general health status, a gender, and a diet of a patient, an administration time, an administration route, a secretion ratio of the composition, a treating period, and simultaneously used drugs. In the case of an adult, when the inhibitor of the gene or protein is administered one to several times a day, 0.01 ng/kg to 10 mg/kg in the case of siRNA, 0.1 ng/kg to 10 mg/kg in the case of the antisense oligonucleotide for mRNA of the gene, 0.1 ng/kg to 10 mg/kg in the case of the compound, and 0.1 ng/kg to 10 mg/kg of the monoclonal antibody for the protein may be administered.
Furthermore, it is apparent to those skilled in the art that the PRKD1-targeting siRNA, an antibody thereof, and the like are prepared as follows.
Antisense Nucleotide
An antisense nucleotide binds (hybridizes) to a complementary base sequence of DNA, immature-mRNA, or mature mRNA as defined in a Watson-click base pair, to interfere with the flow of genetic information as a protein in DNA. The nature of the antisense nucleotide which is specific to a target sequence becomes exceptionally multifunctional. Since the antisense nucleotides are long chains of monomer units, the antisense nucleotides may be easily synthesized with respect to the target RNA sequence. Many recent studies have verified the utility of the antisense nucleotides as a biochemical means for studying the target protein (Rothenberg et al., J. Natl. Cancer Inst., 81:1539-1544, 1999). Since there has been much progress in fields of oligonucleotide chemistry and nucleotide synthesis having improved cell line adsorption, target binding affinity and nuclease resistance, the use of the antisense nucleotide may be considered as a novel type of inhibitor.
Peptide Mimetics
The peptide mimetics is a peptide or non-peptide that inhibits a binding domain of the PRKD1 protein leading to PRKD1 activity. Major residues of a nonhydrolyzable peptide analog may be produced by using β-turn dipeptide cores (Nagai et al. Tetrahedron Lett 26:647, 1985), keto-methylene pseudopeptides (Ewenson et al. J Med chem 29:295, 1986; and Ewenson et al. in Peptides: Structure and Function (Proceedings of the 9th American Peptide Symposium) Pierce chemical co. Rockland, Ill., 1985), azepine (Huffman et al. in Peptides: chemistry and Biology, G. R. Marshall ed., EScOM Publisher: Leiden, Netherlands, 1988), benzodiazepine (Freidinger et al. in Peptides; chemistry and Biology, G. R. Marshall ed., EScOM Publisher: Leiden, Netherlands, 1988), β-aminoalcohol (Gordon et al. Biochem Biophys Res commun 126:419 1985), and a substituted gamma-lactam ring (Garvey et al. in Peptides: chemistry and Biology, G. R. Marshell ed., EScOM Publisher: Leiden, Netherlands, 1988).
siRNA Molecule
It is preferred that a sense RNA and an antisense RNA form a double stranded RNA molecule, in which the sense RNA is a siRNA molecule including the same nucleic acid sequence as the target sequence of some consecutive nucleotides of the PRKD1 mRNA. The siRNA molecule is preferably composed of a sense sequence consisting of 10 to 30 bases selected in the nucleotide sequence of the PRKD1 gene and an antisense sequence complementarily binding to the sense sequence, but it is not limited thereto. Any double-stranded RNA molecule having a sense sequence capable of complementarily binding to the base sequence of the PRKD1 gene may be used. Most preferably, the antisense sequence has a sequence complementary to the sense sequence.
Antibody
The PRKD1 antibody may be prepared through PRKD1 injection or commercially available. Further, the antibody includes a polyclonal antibody, a monoclonal antibody, and a fragment capable of binding to an epitope.
The polyclonal antibodies can be produced by a conventional method of obtaining serum containing the antibodies by injecting the PRKD1 into an animal and collecting blood from the corresponding animal. Such polyclonal antibodies may be purified by any method known in the art and made from any animal species host, such as goats, rabbits, sheep, monkeys, horses, pigs, cows, dogs and the like.
The monoclonal antibodies may be prepared using any technology that provides the production of antibody molecules through the cultivation of continuous cell lines. Such a technology is not limited thereto, but includes a hybridoma technology, a human B-cell line hybridoma technology, and an EBV-hybridoma technology (Kohler G et al., Nature 256:495-497, 1975; Kozbor D et al., J Immunol Methods 81:31-42, 1985; cote R J et al., Proc Natl ACad Sci 80:2026-2030, 1983; and cole S P et al., Mol cell Biol 62:109-120, 1984).
Further, antibody fragments containing specific binding sites for the PRKD1 may be prepared. For example, although not limited thereto, F(ab′)2 fragments may be prepared by decomposing an antibody molecule into pepsin, and Fab fragments may be prepared by reducing disulfide bridges of the F(ab′)2 fragments. Alternatively, monoclonal Fab fragments having the desired specificity may be identified quickly and easily by decreasing a Fab expression library (Huse W D et al., Science 254: 1275-1281, 1989).
The antibody may bind to a solid substrate to facilitate subsequent steps such as washing or separation of the complex. The solid substrate includes, for example, a synthetic resin, nitrocellulose, a glass substrate, a metal substrate, glass fibers, microspheres, microbeads, and the like. In addition, the synthetic resin includes polyester, polyvinyl chloride, polystyrene, polypropylene, PVDF, nylon, and the like.
Aptamer
The aptamer is a single-stranded nucleic acid (DNA, RNA or modified nucleic acid) that has its own stable tertiary structure and is capable of binding to a target molecule with high affinity and specificity. After an aptamer discovery technology called SELEX (Systematic Evolution of Ligands by EXponential enrichment) is first developed Ellington, A D and Szostak, J W., Nature 346:818-822, 1990), many aptamers that can bind to various target molecules, including small molecules, peptides, and membrane proteins have been continuously discovered. The aptamer is comparable to the monoclonal antibody due to its characteristic capable of binding to a target molecule with unique high affinity (usually a pM level) and specificity, and there is a high possibility to be an alternative antibody, especially as a “chemical antibody”.
Various advantages and features of the present disclosure and methods accomplishing thereof will become apparent from the following description of exemplary embodiments with reference to the accompanying drawings. However, the present disclosure is not limited to the following exemplary embodiments but may be implemented in various different forms. The exemplary embodiments are provided only to complete disclosure of the present disclosure and to fully provide a person having ordinary skill in the art to which the present disclosure pertains with the category of the disclosure, and the present disclosure will be defined by the appended claims.
According to the present invention, stemness of breast cancer cells is inhibited by inhibiting expression and/or activity of PRKD1. Therefore, an inhibitor for the expression or activity of PRKD1 can be used for inhibiting proliferation, metastasis or recurrence by stemness of breast cancer and restore the drug sensitivity of breast cancer.
Hereinafter, configurations of the present invention will be described in more detail with reference to detailed Examples. However, it is apparent to those skilled in the art that the scope of the present invention is not limited to only the disclosure of Examples.
Chemical Drug and Reagent
CRT0066101 was purchased from R&D Systems (Minneapolis, Minn., USA); this drug was resuspended in sterile distilled water and used for in vivo studies. To treat CRT0066101, MCF-7-ADR cells (American Type Culture Collection, Manassas, Va., USA) were seeded and 0.1 to 10 μM CRT0066101 was added and incubated for 1 hour. WST-8 was purchased from Enzo Life Sciences, Inc. (Farmingdale, N.Y., USA). PRKD1 siRNA and scrambled siRNA (Santa Cruz Biotechnology, Santa Cruz, Calif., USA) were transfected by using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, Calif., USA).
Cell Culture and Transfection
The breast adenocarcinoma MCF7, MCF-7-ADR and MDAMB-231 cell lines (American Type Culture Collection) were incubated in DMEM (Dulbecco's modified Eagle's Medium; Welgene, Daejeon, South Korea) and 10% FBS (Welgene), 1% penicillin, streptomycin were supplemented in a wet incubator at 37° C. under 5% CO2. For RNAi transfection, MCF-7-ADR cells were seeded in a medium without antibiotics in a 10-cm plate. After 24 hours, cells were transfected with PRKD1 siRNA using Lipofectamine RNAiMAX (Invitrogen). After 48 hours, the cells were collected and analyzed by western blot or resuspended in a breast cancer mammosphere medium. For microRNA transfection, MCF-7-ADR cells were incubated with a miRNA precursor (miR-34a/b/c) for 48 hours using a siPORT NeoFX transfection agent (Ambion; Thermo Fisher, St. Louis, Mo., USA). A miRNA precursor and a negative control precursor were purchased from Thermo Fisher.
qRT-PCR
Quantitative reverse-transcription PCR (qRT-PCR) was performed according to manufacturer's instructions in a SYBR Green-based method using an RG 3000 apparatus (Corbett Robotics, San Francisco, Calif., USA). An ABI-7500 apparatus (Thermo Fisher) was used to evaluate PRKD1 expression in various breast cancer cell lines. All oligonucleotide primers were designed with DNASTAR (Madison, Wis., USA). All qRT-PCR graphs were obtained by using relative Ct (ΔΔCt) values.
Western Blotting and Antibodies
A total of 30 μg of a protein extract was isolated by 8% SDS-PAGE and the protein was electrophoretically transferred to a PVDF membrane. The primary antibodies used were phosphorylated PKD/PKCμ (Ser916), GSK3β, phosphorylated GSK3α (Ser21)/β (Ser9), and β-catenin. These antibodies were purchased from Cell Signaling Technology (Danvers, Mass., USA) and the PKD/PKCμ antibody was purchased from Santa Cruz Biotechnology. (β-actin (Bethyl Laboratories, Montgomery, Tex., USA) was used as a loading control. The membrane was washed with 1×PBS/0.1% Tween 20 and the bound proteins were detected with an enhanced chemiluminescent reagent (Amersham Pharmacia Biotech, Parsippany, N.J., USA).
Luciferase Analysis Method
The 3′-UTR reporter construct of PRKD1 was cloned into a pGL3-control vector and the 3′-UTRs of PRKD1 were amplified from the genomic DNA of HEK293T cells. The miR-34 seed sequence from PRKD1 w was mutated by a PCR-based method and the reporter construct was verified by sequencing. HEK293T cells were transiently transfected with a 3′-UTR reporter construct (1.5 μg per well in a 6-well plate) and 15 nM of a miR-34 family precursor (Ambion) by using Lipofectamine 2000 (Invitrogen). The activity of the 3′-UTR reporter construct was normalized to the activity of cotransfected pCMV-hRL (40 ng per well in a 6-well plate, Promega). After incubation for 24 hours, the cells were lysed with a 1× passive lysis buffer, and the activity was measured using a Dual Luciferase Assay kit (Promega) according to the manufacturer's instructions.
Tumorsphere Formation Assay (TSA)
For incubation of tumorspheres, cells (2000 cells/mL) were suspended and incubated in serum-free DMEM/F12 (welGENE) containing 1% penicillin, B27 (1:50; Gibco; Thermo Fisher), 20 ng/mL of an epidermal growth factor (Prospec, East Brunswick, N.J., (WelGENE) 5 mg/mL of insulin (Sigma-Aldrich, St. Louis, Mo., USA) and 0.4% bovine serum albumin (Sigma-Aldrich). After about 10 days, the plate was analyzed and formation of tumorspheres was verified and quantified with a microscope (Olympus IX71; Olympus, Tokyo, Japan). In order to count the number of tumorspheres, MCF-7-ADR cells were filtered and quantified by a strainer (BD Biosciences, East Rutherford, N.J., USA) having a pore size of 70 μm. Treatment with CRT0066101 was performed on 6-th day and 8-th day after incubation.
Surface Marker Analysis Using Flow Cytometry
Cells were collected after transfection with RNAi of PRKD1 or CRT0066101 treatment and expression of CD44+/CD24-surfaces was evaluated. The cells were washed with 2% FBS, stained with anti-CD44 (APC-conjugated; BD Biosciences) and anti-CD24 (BD Biosciences) in a PBS containing 2% FBS, and placed on ice in the dark for 30 minutes. The cells were washed again with a cold PBS buffer, loaded with >10,000 cells in a BD CantoII flow cytometer (BD Biosciences), and then analyzed by flow cytometry using FACSDiVa software (BD Biosciences).
Analysis of Cell Survival Rate
MCF-7-ADR cells were placed in a 24-well plate and incubated for 72 hours together with CRT0066101 at various concentrations (0.1, 0.5, 1, 5, and 10 μM). Cell survival rate was analyzed by WST-8 assay (Sigma-Aldrich) and an optical density was measured at 450 nm using a microplate reader.
Fluorescence Immunohistochemistry
A control or miR-32a overexpressed tumor and a carrier or CRT0066101 treated tumor were cut and paraffin-treated slides were used. The paraffin was removed from the slides, rehydrated 3 to 4 times in Histoclear, and then passed sequentially through ethanol at different concentrations (100%, 95%, 80%, and 70%). Antigen reconstitution was performed by immersing fragments in a 0.01M citric acid solution (pH 6.0) and boiling the fragments in a microwave for 15 minutes. In the case of TUNEL analysis, an in-situ apoptosis detection kit, a fluorescent material (Roche, Indianapolis, USA) labeled apoptotic cells, and a Ki-67 primary antibody (Vector Lab, USA) were applied to the fragments and incubated at 4° C. overnight. Thereafter, the slides were incubated with DAPI and secondary antibody for two hours. Finally, the slides were treated with a mounting solution (Dako) and a photograph was taken with a confocal microscope (Zeiss).
Preparation of Breast Cancer Xenografted Mice
All studies, including the use of nude mice, were approved by the committee on animal protection and use of the Yonsei University Medical center (2015-0087) and performed under conditions according to facilities without specific pathogens and the guideline of the committee. Mice were anesthetized with 150 μl saline/zoletil/rompun (7:1:1) outside each femoral region and subcutaneously injected with 1.5×106 of MCF-7-ADR cells. Six mice were randomly grouped and started to be treated from 10-th day after tumor graft. CRT0066101 was administered orally to a tumor-bearing animal and administered with 1.6 mg/kg every time, 5 times per week, for 4 weeks. The tumor size was measured every 3 to 4 days using a caliper from formation of touched tumor to termination and the tumor volume was calculated by Equation of length×width2×0.5236. The mice were sacrificed in a 7.5% CO2 chamber and tumors were isolated and used for immunohistochemistry and other assays.
Result 1: MiR-34a Inhibits PRKD1 in MCF-7-ADR Cells
PRKD1 expression was evaluated in breast cancer cell lines including MCF-10A, MCF-7, ZR-75-1, MCF-7-ADR, SK-BR-3, MDA-MB-231 and MDAMB-468. As a result, the PRKD1 expression level was increased in MCF-7-ADR cells (see
In the MCF-7-ADR cells, the expression levels of miR-34b and miR-34c were also detected, but no significant down regulation was observed (
Result 2: PRKD1 Promotes Breast Cancer Stemness Through GSK3/β-Catenin Signaling
In order to investigate PRKD1 inhibition in tumor stem cells, MCF-7-ADR cells were transfected with a miR-34a precursor and PRKD1 siRNAs. After transfection, the expression level of miR-34a was increased and the level of PKD/PKCμ was decreased compared to a negative control (
PRKD1 phosphorylation of β-catenin in Thr112/Thr120 may be crucial for cell-cell junctions in prostate cancer cells [20]. Furthermore, the complex of CDC42, PAR6 and PKCζ binds to GSK3β and catalyzes phosphorylation of Ser9 to inhibit GSK3β [21]. In order to correlate PRKD1 with GSK3/β-catenin signaling, western blot analysis was performed. The result showed that PKD/PKCμ reduction inhibited β-catenin expression and phosphorylation of GSK3α and GSKβ (
PRKD1 expression and GSK3/β-catenin signaling were up-regulated in MCF-7-ADR cells forming tumorspheres (
Result 3: PKD/PKCμ Phosphorylation Inhibition Reduces Self-Renewal Capacity of Breast Cancer Stem Cells
It was found that a PKD/PKCμ phosphorylation-related had two possible active pathways. One is protein kinase C (PKC)-dependent phosphorylation (Ser744/Ser748) and the other is autophosphorylation (Ser916). For sufficient activation, autophosphorylation needs to occur immediately after PKC-dependent phosphorylation [10, 11]. CRT0066101 is an inhibitor that targets PKD autophosphorylation [16]. In order to determine a role of PKD/PKCμ autophosphorylation, MCF-7-ADR cells were treated with 1 μM or 5 μM of CRT0066101. As a result of western blotting, CRT0066101 inhibited phosphorylation of PKD/PKCμ and GSK3/β-catenin in MCF-7-ADR cells (
The number of tumorspheres (>70 μm) after treatment of CRT0066101 (1 μM or 5 μM) decreased dose-dependently compared to the control (
Result 4: PRKD1 Restores Drug Resistance
As above study results, it was reported that PKD/PKCμ is associated with apoptosis through caspase-3 inhibition [22]. Therefore, the present inventors examined whether PRKD1 inhibition activated apoptosis in MCF-7-ADR cells. As a result, it was found that the reduction reaction further occurred in beast cancer stem cells. As illustrated in
Result 5: in the Xenograft Model, Inhibition or Down-Regulation of PKCμ Function Inhibits Tumor Growth
In preceding studies of the present inventors, the present inventors verified that miR-34a inhibits NOTCH1 expression in nude mice to inhibit tumor formation [5]. In the present invention, whether the down-regulation of PRKD1 by miR-34a inhibits tumor growth in the xenograft model has been studied. The expression level of PRKD1 was down-regulated in miR-34a overexpressed tumor compared to the control tumor (
In order to further evaluate the inhibitory effect of PKD/PKCμ, mice having tumor xenografted and established with MCF-7-ADR cells were treated with 65 mg/kg of CRT0066101 daily for 4 weeks. The tumor size in the CRT0066101-treated mice was reduced compared to the untreated control (
The PRKD1 is involved in cell proliferation, apoptosis, cell junction, invasion and vesicle trafficking [23]. Interestingly, PRKD1 expression has a different pattern in various tumor cells and performs dual functions as a tumor cell or tumor inhibitor [24]. The PRKD1 expression is down-regulated in invasive human breast cancer compared with a normal breast tissue [25]. Similar expression patterns were verified in microarray analysis and invasive cell models such as SK-BR-3, T-47D and MDA-MB-231 [25 and 26]. Furthermore, when PRKD1 promoter methylation is returned, invasion and metastasis of breast cancer cells are blocked [27]. The experimental results of the present inventors show that the PRKD1 expression patterns in a MCF-7-ADR cell line increase drug resistance. The PRKD1 was highly expressed in a drug resistant cell line including doxorubicin-resistant MCF-7-ADR cells, tamoxifen-resistant LCC2 cells, and tamoxifen and fluvestrant-resistant LCC9 cells. Accordingly, we concluded that PRKD1 expression is associated with drug resistance. The present inventors studied expression of miR-34a and PRKD1 in a TCGA data set (
The miRNA miR-34a plays an important role in tumor inhibition. In conventional studies, it has been reported that miR-34a inhibits tumor stem cells in various tumors including prostate cancer [28], pancreatic cancer [29], medulloblastomas [30] and glioblastomas [31]. This molecule also inhibits tumor cell survival, tumor stemness, metastasis, and chemical resistance while inhibiting targets associated with cell cycle, differentiation, and apoptosis [17]. In the present invention, it was verified that miR-34a negatively regulates the PRKD1 in MCF-7-ADR cells. In addition, the PRKD1 is a new target of miR-34a and found that the miR-34a binds to PRKD1 3′-UTR. Furthermore, the present inventors have found that miR-34a-PRKD1 interaction plays an important role in overcoming tumor stemness and drug resistance in a breast cancer cell line. In the preceding studies, it was reported that the PRKD1 phosphorylates β-catenin at Thr112/Thr120 and overexpression of PRKD1 inhibits β-catenin-mediated transcriptional activity [32]. β-catenin phosphorylation occurs through GSK3, and the GSK3 targets β-catenin as a part of a Wnt-signaling protein complex [33]. In addition, GSK3β is a kinase that is involved in prostate cancer cellization and migration through a Wnt-independent mechanism [34]. In the present invention, it has been observed that the reduced PRKD1 inhibits the self-renewal capacity of breast cancer stem cells through the modification of GSK3/β-catenin signaling. Therefore, these results indicate that the PRKD1 activates breast cancer stemness through GSK3/β-catenin signaling.
Harikumar and the like discovered CRT0066101 as an inhibitor specific to all PKD isoforms [16] and found that the CRT0066101 blocked growth of pancreatic cancer by inhibiting PRKD1 autophosphorylation [16]. The present inventors blocked PRKD1 activation by treating breast cancer cell lines and xenograft models with CRT0066101. This result indicates that CRT0066101 may be a potential therapeutic agent for breast cancer patients.
In the present invention, PRKD1 overexpression in the MCF-7-ADR cell line had a negative correlation with miR-34a overexpression. The present inventors found that miR-34a binds to PRKD1 3′-UTR to inhibit cancer cell stemness in breast cancer stem cells through the GSK3/β-catenin signaling pathway. Furthermore, the present inventors found that CRT0066101, known as the PRKD1 inhibitor, affects the reduction of breast cancer stem cells and drug resistance through the GSK3/β-catenin signaling pathway (
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2016-0071126 | Jun 2016 | KR | national |
| 10-2017-0071824 | Jun 2017 | KR | national |
| Number | Name | Date | Kind |
|---|---|---|---|
| 20040180848 | Fesik | Sep 2004 | A1 |
| Number | Date | Country |
|---|---|---|
| WO 2009099991 | Feb 2009 | WO |
| WO 2009147246 | Jun 2009 | WO |
| Entry |
|---|
| Kim et al. (Oncotarget, 2016 vol. 7:14791-14802). |
| No Two Cancers are the Same. Cancer Research Wales, https://www.cancerresearchwales.co.uk/blog/no-two-cancers-are-the-same, downloaded on Jul. 3, 2019. |
| Sundram et al. (Mol Cancer Res. Aug. 2011; 9(8): 985-996). |
| Rozengurt et al. (Journal of Biological Chemistry, vol. 280, No. 14, Issue of Apr. 8, pp. 13205-13208, 2005). |
| Cui J et al., MiR-873 Regulates ERα Transcriptional Activity and Tamoxifen Resistance via Targeting CDK3 in Breast Cancer Cells, Chemistry Faculty Publications, Oncogene (2014), pp. 1-13, Macmillan Publishers Limited. |
| Chaffer CL, Weinberg RA, A Perspective on Cancer Cell Metastasis, Science, Mar. 25, 2011, p. 1559-1564, vol. 331, American Association for the Advancement of Science, Washington, DC. |
| Li Laisheng et al., MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1, Clinical and experimental medicine. (2013) 13, pp. 109-117, Springer-Verlag 2012. |
| Visvader JE, Lindeman GJ, Cancer stem cells in solid tumours: accumulating evidence and unresolved questions, Nat. Rev. Cancer, Oct. 2008, pp. 755-768, vol. 8, Macmillan Publishers Limited. |
| Park EY et al., Targeting of miR34a-NOTCH1 Axis Reduced Breast Cancer Stemness and Chemoresistance, Cancer research; 74(24), Dec. 15, 2014, pp. 7573-7582, American Association for Cancer Research. |
| Liu S et al., Role of microRNAs in the Regulation of Breast Cancer Stem Cells, Journal of Mammary Gland Biology and Neoplasia (2012) 17, pp. 15-21, Springer Science+Business Media, LLC. |
| Schwarzenbacher D et al., The Role of MicroRNAs in Breast Cancer Stem Cells, International Journal of Molecular Sciences 2013, 14, pp. 14712-14723. |
| Yu F et al., MicroRNA 34c Gene Down-regulation via DNA Methylation Promotes Self-renewal and Epithelial-Mesenchymal Transition in Breast Tumor-initiating Cells, The Journal of Biological Chemistry, Jan. 2, 2012, pp. 465-473, vol. 287, No. 1, The American Society for Biochemistry and Molecular Biology, Inc., U.S.A. |
| Fu Y, Rubin, CS., Protein kinase D: coupling extracellular stimuli to the regulation of cell physiology, EMBO reports 2011, pp. 785-796, vol. 12, No. 8, European Molecular Biology Organization. |
| Iglesias T et al., Identification of in Vivo Phosphorylation Sites Required for Protein Kinase D Activation*, The Journal of biological chemistry, Issue of Oct. 16, 1998, pp. 27662-27667, vol. 273, No. 42, The American Society for Biochemistry and Molecular Biology, Inc., U.S.A. |
| Valverde AM. et al., Molecular cloning and characterization of protein kinase D: A target for diacylglycerol and phorbol esters with a distinctive catalytic domain, Biochemistry, Proceedings of the National Academy of Sciences of the United States of America, Aug. 1994, pp. 8572-8576, vol. 91. |
| Rozengurt E et al., Protein Kinase D Signaling*, Minireview, The Journal of biological chemistry, Issue of Apr. 8 2005, pp. 13205-13208, vol. 280, No. 14, The American Society for Biochemistry and Molecular Biology, Inc., U.S.A. |
| Jacamo R et al., Sequential Protein Kinase C (PKC)-dependent and PKC-independent Protein Kinase D Catalytic Activation via Gq-coupled Receptors Differential REGULATIONOFACTIVATIONLOOPSER744ANDSER748 Phosphorylation*, The Journal of Biological Chemistry, May 9, 2008, pp. 12877-12887, vol. 283, No. 19, The American Society for Biochemistry and Molecular Biology, Inc., U.S.A. |
| Storz P et al., Protein Kinase D mediates a stress-induced NF-kB activation and survival pathway, The EMBO journal 2003, pp. 109-120, vol. 22 No. 1. |
| Sinnett-Smith J et al., Protein Kinase D Potentiates DNA Synthesis Induced by Gq-coupled Receptors by Increasing the Duration of ERK Signaling in Swiss 3T3 Cells*, The Journal of biological chemistry Issue of Apr. 16, 2004, pp. 16883-16893, vol. 279, No. 16, The American Society for Biochemistry and Molecular Biology, Inc., U.S.A. |
| Harikumar KB et al., A Novel Small-Molecule Inhibitor of Protein Kinase D Blocks Pancreatic Cancer Growth In vitro and In vivo, Research Article, Molecular cancer therapeutics; 9(5) May 2010, pp. 1136-1146, American Association for Cancer Research. |
| Misso G et al., Therapeutic Aptamers March On, Molecular therapy-Nucleic acids (2014) 3, e194, The American Society of Gene & Cell Therapy. |
| Achari C et al., Expression of miR-34c induces G2/M cell cycle arrest in breast cancer cells, Research Article, BMC cancer 2014, 14:538, pp. 1-9, BioMed Central Ltd. |
| Kato M et al., The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells, Oncogene (2009) 28, pp. 2419-2424, Macmillan Publishers Limited. |
| Du C et al., Protein Kinase D1-Mediated Phosphorylation and Subcellular Localization of B-Catenin, Research Article, Cancer research Feb. 1, 2009, 2009; 69: (3), pp. 1117-1124, American Association for Cancer Research. |
| Jope RS et al., Glycogen Synthase Kinase-3 (GSK3): Inflammation, Diseases, and Therapeutics, Neurochemical Research (2007) 32, pp. 577-595, Springer Science+Business Media, Inc. |
| Yuan J et al., Protein kinase D regulates cell death pathways in experimental pancreatitis, Original Research Article, Mar. 27, 2012, pp. 1-17, vol. 3 Art. 60, Gastrointestinal Sciences, Frontiers in Physiology. |
| Jaggi M et al., Protein kinase D1: A Protein of emerging translational interest, Article in Frontiers in bioscience 12, May 1, 2007, pp. 3757-3767. |
| Sundram V et al., Emerging Roles of Protein Kinase D1 in Cancer, Subject Review, Molecular Cancer Research 9 (8), Aug. 2011, pp. 985-996, American Association for Cancer Research. |
| Eiseler T et al., Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion, Research article, Breast cancer research 2009, pp. 1-12, vol. 11 No. 1, BioMed Central Ltd. |
| Bowden ET et al., An invasion-related complex of cortactin, paxillin and PKCm associates with invadopodia at sites of extracellular matrix degradation, Complex of cortactin, paxillin and PKCm in invadopodia, Oncogene 1999; 18, pp. 4440-4449, Stockton Press. |
| Borges S et al., Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis, Breast cancer research 2013, 15:R66, pp. 1-15, BioMed Central Ltd. |
| Liu C et al., The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44, Nature medicine, Feb. 2011, pp. 211-215, vol. 17 No. 2, Nature America, Inc. |
| Nallas D et al., Targeting Epigenetic Regulation of miR-34a for Treatment of Pancreatic Cancer by Inhibition of Pancreatic Cancer Stem Cells, PloS one, Aug. 2011, pp. 1-12, vol. 6 Issue 8 e24099. |
| Stankevicins L et al., MiR-34a is up-regulated in response to low dose, low energy X-ray induced DNA damage in breast cells, Radiation oncology 2013; 8:231, pp. 1-8, BioMed Central Ltd. |
| Guessous F et al., microRNA-34a is tumor suppressive in brain tumors and glioma stem cells, Cell cycle, Mar. 15, 2010, pp. 1031-1036, vol. 9 Issue 6, Landes Bioscience. |
| Jaggi M et al., E-Cadherin Phosphorylation by Protein Kinase D1/Protein Kinase CM is Associated with Altered Cellular Aggregation and Motility in Prostate Cancer, Research Article, Cancer research 2005; 65: (2). Jan. 15, 2005, pp. 483-492, American Association for Cancer Research. |
| Ciani L, Salinas PC, WNTS in the Vertebrate Nervous System: From Patterning to Neuronal Connectivity, Nat Rev Neurosci., May 2005; pp. 351-362, vol. 6, Nature Publishing Group. |
| Kroon J et al., Glycogen synthase kinase-3β inhibition depletes the population of prostate cancer stem/progenitor-like cells and attenuates metastatic growth, Oncotarget, Dec. 5, 2013, pp. 8986-8994, 2014, vol. 5, No. 19. |
| Number | Date | Country | |
|---|---|---|---|
| 20170369887 A1 | Dec 2017 | US |
